Posted On: 08/24/2015 8:02:15 AM
Post# of 72447
Looks like Spot is getting desperate over there.
From the PR.
"The FDA also encourages development of drugs and biologics to prevent and treat rare pediatric diseases through its Pediatric Disease Priority Review Voucher (PPRV) incentive program. The program is set to expire in March 2016, but could be extended under a provision in the 21st Century Cures Act. Last week United Therapeutics Corporation agreed to sell its Priority Review Voucher to AbbVie for $350 Million."
From the PR.
"The FDA also encourages development of drugs and biologics to prevent and treat rare pediatric diseases through its Pediatric Disease Priority Review Voucher (PPRV) incentive program. The program is set to expire in March 2016, but could be extended under a provision in the 21st Century Cures Act. Last week United Therapeutics Corporation agreed to sell its Priority Review Voucher to AbbVie for $350 Million."
(0)
(0)
